Terril Brothers Inc. trimmed its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 0.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 57,915 shares of the biotechnology company’s stock after selling 168 shares during the period. Biogen makes up approximately 5.8% of Terril Brothers Inc.’s holdings, making the stock its 8th largest position. Terril Brothers Inc.’s holdings in Biogen were worth $18,134,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Assenagon Asset Management S.A. bought a new stake in shares of Biogen during the third quarter valued at approximately $123,494,000. Botty Investors LLC increased its position in shares of Biogen by 75.0% during the second quarter. Botty Investors LLC now owns 11,232 shares of the biotechnology company’s stock valued at $3,048,000 after acquiring an additional 4,812 shares in the last quarter. BB&T Securities LLC increased its position in shares of Biogen by 25.0% during the second quarter. BB&T Securities LLC now owns 12,989 shares of the biotechnology company’s stock valued at $3,524,000 after acquiring an additional 2,598 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Biogen by 2.4% during the first quarter. Vanguard Group Inc. now owns 14,352,490 shares of the biotechnology company’s stock valued at $3,924,258,000 after acquiring an additional 342,568 shares in the last quarter. Finally, Neuberger Berman Group LLC increased its position in shares of Biogen by 18.6% during the second quarter. Neuberger Berman Group LLC now owns 27,974 shares of the biotechnology company’s stock valued at $7,591,000 after acquiring an additional 4,389 shares in the last quarter. Hedge funds and other institutional investors own 88.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Biogen Inc. (BIIB) Stake Lessened by Terril Brothers Inc.” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/biogen-inc-biib-stake-lessened-by-terril-brothers-inc/1707627.html.

Several equities research analysts recently weighed in on the stock. Mizuho set a $400.00 price target on shares of Biogen and gave the company a “buy” rating in a research report on Monday. Oppenheimer Holdings, Inc. initiated coverage on shares of Biogen in a research report on Thursday, November 9th. They issued an “outperform” rating and a $350.00 target price for the company. BMO Capital Markets lifted their target price on shares of Biogen from $381.00 to $386.00 and gave the stock an “outperform” rating in a research report on Monday, November 6th. Canaccord Genuity initiated coverage on shares of Biogen in a research report on Friday, October 27th. They issued a “hold” rating and a $340.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $340.00 target price on shares of Biogen in a research report on Wednesday, October 25th. Twelve analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $341.89.

Shares of Biogen Inc. (BIIB) traded up $3.91 during trading hours on Thursday, reaching $314.19. 330,434 shares of the company traded hands, compared to its average volume of 1,515,812. The company has a market cap of $66,360.00, a P/E ratio of 14.34, a price-to-earnings-growth ratio of 1.93 and a beta of 0.72. Biogen Inc. has a one year low of $244.28 and a one year high of $348.84. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.19 and a quick ratio of 1.90.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.70 by $0.61. The company had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The firm’s revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.19 EPS. analysts predict that Biogen Inc. will post 22.03 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.